13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
45 檔
33.5%
The Q1 2024 SEC filing reveals that Blue Owl Capital Holdings LP held a total portfolio value of $664.5M, covering 45 public equity positions.
In Q1 2024, Blue Owl Capital Holdings LP displayed an active expansion posture, initiating 7 new positions and adding to 15 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HOOD | Robinhood Markets Inc - A | Stock-Financials | 10.78% | — | — | |
| 2 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 9.96% | -3.07% | -14.47% | |
| 3 | PLRX | Pliant Therapeutics Inc | Stock-Other | 8.94% | -1.01% | EXIT | |
| 4 | ✓ | Engene Holdings Inc | Stock-Other | 8.33% | -8.08% | EXIT | |
| 5 | TRML | Tourmaline Bio Inc | Stock-Other | 6.39% | — | +8.64% | |
| 6 | OBDC | Blue Owl Capital CORP | Stock-Financials | 6.28% | -2.73% | — | |
| 7 | KVYO | Klaviyo Inc-a | Stock-Other | 6.10% | — | — | |
| 8 | LRMR | Larimar Therapeutics Inc | Stock-Other | 6.06% | -4.40% | +16.99% | |
| 9 | ✓ | Acelyrin Inc | Stock-Other | 3.81% | — | +23.25% | |
| 10 | EVCM | Evercommerce Inc | Stock-Other | 3.09% | — | — | |
| 11 | RPTX | Repare Therapeutics Inc | Stock-Other | 2.94% | — | — | |
| 12 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.50% | -0.78% | +1.90% | |
| 13 | KROS | Keros Therapeutics Inc | Stock-Other | 2.28% | — | -51.04% | |
| 14 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.94% | — | — | |
| 15 | IRON | Disc Medicine Inc | Stock-Other | 1.93% | — | +10.69% | |
| 16 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 1.81% | +1.00% | +371.01% | |
| 17 | TOST | Toast Inc-class A | Stock-Tech | 1.61% | — | -94.52% | |
| 18 | ETWOGBP | E2open Parent Holdings Inc | Stock-Other | 1.46% | — | — | |
| 19 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.40% | — | -4.80% | |
| 20 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.12% | -2.99% | — | |
| 21 | ✓ | Ikena Oncology Inc | Stock-Other | 1.10% | — | +99.18% | |
| 22 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.00% | — | +53.85% | |
| 23 | DELL | Dell Technologies -c | Stock-Tech | 0.94% | +1.53% | +17.54% | |
| 24 | OHI | Omega Healthcare Investors, Inc. | Stock-Real Estate | 0.77% | — | — | |
| 25 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.74% | -0.91% | — | |
| 26 | LABDUSD | Drx Dly S&p Biotech Bear 3x | ETF-Tech | 0.71% | — | +44.12% | |
| 27 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.71% | — | — | |
| 28 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.70% | — | — | |
| 29 | ✓ | Adc Therapeutics SA | Stock-Other | 0.66% | -0.58% | — | |
| 30 | IMVT | Immunovant Inc | Stock-Other | 0.65% | — | +66.67% | |
| 31 | ✓ | Engene Holdings Inc | Stock-Other | 0.53% | -0.35% | EXIT | |
| 32 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.53% | -1.14% | EXIT | |
| 33 | BRZE | Braze Inc-a | Stock-Other | 0.47% | — | +555.27% | |
| 34 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.36% | — | -77.17% | |
| 35 | SNOW | Snowflake Inc | Stock-Tech | 0.25% | — | — | |
| 36 | GTLB | Gitlab Inc-cl A | Stock-Tech | 0.24% | — | — | |
| 37 | BLND | Blend Labs Inc-a | Stock-Other | 0.23% | — | — | |
| 38 | GOCOQ | Gohealth Inc-class A | Stock-Other | 0.17% | -0.02% | EXIT | |
| 39 | ✓ | Desktop Metal Inc Class A Comm | Stock-Other | 0.13% | — | — | |
| 40 | ✓ | Rallybio CORP | Stock-Other | 0.13% | — | — | |
| 41 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 42 | DTIL | Precision Biosciences Inc | Stock-Other | 0.05% | — | — | |
| 43 | ✓ | Fathom Digital Mfg CORP | Stock-Other | 0.05% | — | — | |
| 44 | UBER | Uber Technologies Inc | Stock-Industrials | 0.02% | — | +286.58% | |
| 45 | ✓ | Alpha Partners Technology Merg | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Engene Holdings Inc | +5.6% | +99.34% | Add |
| 2 | EVCM | Evercommerce Inc | +3.1% | NEW | New buy |
| 3 | LRMR | Larimar Therapeutics Inc | +2.4% | +16.99% | Add |
| 4 | CGEM | Cullinan Therapeutics Inc | +1.6% | -14.47% | Trim |
| 5 | SGMT | Sagimet Biosciences Inc-a | +1.4% | +371.01% | Add |
| 6 | AQST | Aquestive Therapeutics Inc | +0.7% | NEW | New buy |
| 7 | MDGL | Madrigal Pharmaceuticals Inc | +0.7% | NEW | New buy |
| 8 | ✓ | Inozyme Pharma Inc | +0.7% | — | Unchanged |
| 9 | ✓ | Engene Holdings Inc | +0.4% | +7.60% | Add |
| 10 | ✓ | Adc Therapeutics SA | +0.4% | — | Unchanged |
| 11 | DELL | Dell Technologies -c | +0.3% | +17.54% | Add |
| 12 | SNOW | Snowflake Inc | +0.3% | NEW | New buy |
| 13 | BRZE | Braze Inc-a | +0.2% | +555.27% | Add |
| 14 | GTLB | Gitlab Inc-cl A | +0.2% | NEW | New buy |
| 15 | MLYS | Mineralys Therapeutics Inc | +0.2% | -4.80% | Trim |
| 16 | BDTX | Black Diamond Therapeutics I | +0.2% | — | Unchanged |
| 17 | ✓ | Ikena Oncology Inc | +0.2% | +99.18% | Add |
| 18 | TOST | Toast Inc-class A | +0.2% | -94.52% | Trim |
| 19 | ELVN | Enliven Therapeutics Inc | +0.1% | NEW | New buy |
| 20 | CMPX | Compass Therapeutics Inc | +0.1% | — | Unchanged |
| 21 | MLTX | Moonlake Immunotherapeutics | +0.1% | +53.85% | Add |
| 22 | IMVT | Immunovant Inc | +0.1% | +66.67% | Add |
| 23 | DTIL | Precision Biosciences Inc | +0.1% | NEW | New buy |
| 24 | OHI | Omega Healthcare Investors, Inc. | 0% | — | Unchanged |
| 25 | BLND | Blend Labs Inc-a | 0% | — | Unchanged |
| 26 | ✓ | Desktop Metal Inc Class A Comm | — | — | Unchanged |
| 27 | ✓ | Fathom Digital Mfg CORP | — | — | Unchanged |
| 28 | ✓ | Alpha Partners Technology Merg | — | — | Unchanged |
| 29 | IRON | Disc Medicine Inc | 0% | +10.69% | Add |
| 30 | ✓ | -0.1% | EXIT | Sold out | |
| 31 | UBER | Uber Technologies Inc | -0.1% | +286.58% | Add |
| 32 | MIRM | Mirum Pharmaceuticals Inc | -0.1% | EXIT | Sold out |
| 33 | ✓ | Rallybio CORP | -0.1% | — | Unchanged |
| 34 | LABDUSD | Drx Dly S&p Biotech Bear 3x | -0.1% | +44.12% | Add |
| 35 | GOCOQ | Gohealth Inc-class A | -0.1% | — | Unchanged |
| 36 | ✓ | -0.1% | EXIT | Sold out | |
| 37 | OVID | Ovid Therapeutics Inc | -0.1% | — | Unchanged |
| 38 | ETWOGBP | E2open Parent Holdings Inc | -0.3% | — | Unchanged |
| 39 | ✓ | Acelyrin Inc | -0.3% | +23.25% | Add |
| 40 | RARE | Ultragenyx Pharmaceutical In | -0.5% | +1.90% | Add |
| 41 | ✓ | Orchard Therapeutics PLC | -0.6% | EXIT | Sold out |
| 42 | OBDC | Blue Owl Capital CORP | -0.9% | — | Unchanged |
| 43 | KROS | Keros Therapeutics Inc | -1.1% | -51.04% | Trim |
| 44 | TRML | Tourmaline Bio Inc | -1.4% | +8.64% | Add |
| 45 | KVYO | Klaviyo Inc-a | -1.4% | — | Unchanged |
| 46 | 2655787D | Blueprint Medicines CORP | -1.6% | EXIT | Sold out |
| 47 | SYRS | Syros Pharmaceuticals Inc | -1.7% | -77.17% | Trim |
| 48 | HOOD | Robinhood Markets Inc - A | -2.1% | — | Unchanged |
| 49 | RPTX | Repare Therapeutics Inc | -2.5% | — | Unchanged |
| 50 | PLRX | Pliant Therapeutics Inc | -4.1% | — | Unchanged |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 45 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HOOD, CGEM, PLRX) accounted for 33.5% of total reported equity market value during Q1 2024.
Top New Position Initiated
EVCM
市值: $15.5M
Top Position Liquidated / Trimmed
2655787D
前期市值: $6.6M
During Q1 2024, Blue Owl Capital Holdings LP's top holdings by market value included HOOD (10.8%)、CGEM (10.0%)、PLRX (8.9%). The largest single position, HOOD, represented 10.8% of total portfolio value.
In Q1 2024, Blue Owl Capital Holdings LP made 32 total portfolio adjustments, initiating 7 new buys, adding to 15 positions, trimming 5 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.